// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients

Andras Perl - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis

Elisa Alessandri - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

Hydroxychloroquine

Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon

Federica Goegan - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

Hydroxychloroquine

Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity

Barbara Dreo - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States

Kelley Brady - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial

Atul Deodhar - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

Hydroxychloroquine

Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial

Esther Mossel - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Elevated Serum Interleukin-23 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity, Clinical and Immunological Markers

Anita Laloo - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multi-Ethnic Cohort

Daniela Dominguez - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals

Dennisse Bonilla - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease

Alejandra Londono Jimenez - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus

Hydroxychloroquine

Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE

Daniel Goldman - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Hydroxychloroquine

From Diagnosis to the Establishment of the Labalaba Foundation: My Journey from Surviving to Thriving

Courtnie Phillip - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Pulmonary arterial hypertension

Hydroxychloroquine

Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry

Zara Izadi - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Gene-Expression Analysis of Male and Female SLE Patients Reveals Candidate Pathogenic Pathways

David Fernandez - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls

Jessica Li - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Hydroxychloroquine

Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution

Jakrapun Pupaibool - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematous

Jessica Li - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Lupus

Hydroxychloroquine

Hydroxychloroquine Increases Low C3 in SLE

Jessica Li - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels

Benoit Blanchet - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved